Published in Medicine and Law Weekly, July 7th, 2006
The U.S. patent (U.S. Patent No. 7,056,704) broadly covers methods of making small interfering RNAs (siRNAs), the molecules that mediate RNAi. The issued patent is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Garching Innovation GmbH, the licensing agent for the Max Planck Society.
The new patent stems from groundbreaking research published in 2001 in the journal Nature by Thomas Tuschl, PhD, a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.